Chemical inhibitors of MTMR14 can exert their inhibitory effects through various mechanisms related to the protein's cellular functions. 3-Methyladenine and Spautin-1 both target autophagic processes that are crucial for MTMR14's function. By blocking autophagosome formation, 3-Methyladenine directly impedes the autophagic pathway that MTMR14 is a part of, leading to a reduction in its dephosphorylation activity. Spautin-1 operates by inhibiting ubiquitin-specific peptidases, which results in an autophagy blockade, thereby decreasing the dephosphorylation activity of MTMR14 through impaired autophagy. Chloroquine and Bafilomycin A1 disrupt lysosomal function, with Chloroquine raising lysosomal pH and impairing lysosome-autophagosome fusion, and Bafilomycin A1 specifically targeting V-ATPase, which prevents autophagosome-lysosome fusion, a process required by MTMR14 to carry out its role in autophagy. Similarly, Concanamycin A inhibits V-ATPase, disrupting the acidification of autophagosomes and inhibiting MTMR14's function.
The second paragraph focuses on inhibitors that disrupt signaling pathways and membrane dynamics. Wortmannin and LY294002 are phosphoinositide 3-kinase (PI3K) inhibitors that reduce phosphatidylinositol (3,4,5)-trisphosphate levels, which affects the substrate availability for MTMR14, thus inhibiting its enzymatic activity. Saracatinib, by inhibiting Src kinase, can alter cytoskeletal dynamics, which potentially impacts MTMR14's role in endosomal dynamics and function. NSC23766, an inhibitor of Rac1, affects actin cytoskeleton remodeling and membrane ruffling, processes in which MTMR14 is involved, resulting in functional inhibition of the protein. Similarly, PP2, a Src family kinase inhibitor, affects signaling pathways and cellular processes regulated by MTMR14, thereby leading to its functional inhibition. Z-VAD-FMK, as a pan-caspase inhibitor, reduces apoptosis, a process during which MTMR14 is implicated, and thus indirectly inhibits its activation. Lastly, GW4869 disrupts ceramide biosynthesis and vesicular trafficking by inhibiting neutral sphingomyelinase, which are cellular processes involving MTMR14, leading to the inhibition of its enzymatic function in these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
Acts as an autophagy inhibitor by blocking autophagosome formation, which is a process MTMR14 is involved in. Inhibition of autophagy can lead to reduced dephosphorylation activity of MTMR14. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Is a potent phosphoinositide 3-kinase (PI3K) inhibitor and by inhibiting PI3K, it can indirectly inhibit MTMR14 which is known to act on phosphoinositides. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Also a PI3K inhibitor, can reduce phosphatidylinositol (3,4,5)-trisphosphate levels, impacting MTMR14's substrate availability and thus inhibiting its function. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Selectively inhibits autophagy by targeting ubiquitin-specific peptidase 10 (USP10) and USP13, leading to decreased dephosphorylation activity of MTMR14 due to impaired autophagy. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
As a lysosomotropic agent, it raises lysosomal pH, impairing lysosome-autophagosome fusion, a process important for MTMR14 function, thereby inhibiting its activity. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Specifically inhibits V-ATPase, leading to disrupted autophagosome-lysosome fusion, which is a step required for MTMR14's role in autophagy, thus inhibiting its function. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $113.00 $1035.00 | 7 | |
Src kinase inhibitor that can affect the cytoskeleton, potentially altering membrane trafficking and impacting MTMR14's role in endosomal dynamics and function. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $74.00 | 256 | |
A pan-caspase inhibitor that can inhibit apoptosis, during which MTMR14 is implicated. Reduced apoptosis can lead to decreased activation of MTMR14. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
Inhibits Rac1, affecting actin cytoskeleton remodeling and membrane ruffling, processes that MTMR14 is possibly involved in, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Inhibits Src family kinases, which can affect signaling pathways and cellular processes including those regulated by MTMR14, thus inhibiting its activity. | ||||||